SS Innovations shares surge 10.72% premarket after telesurgery approvals in Indonesia and Philippines boost adoption outlook.

SS Innovations International (SSII) surged 10.72% in premarket trading following regulatory approvals for telesurgeries using its SSi Mantra surgical robotic system in Indonesia and the Philippines, alongside surpassing 150 cumulative telesurgeries. These developments highlight early traction for its remote surgery technology, expanding its real-world adoption beyond its Indian base. Despite reporting 2025 full-year revenue of $42.48 million (up from $20.65 million) and narrowing its net loss to $12.13 million, the company faces ongoing losses and auditor concerns about its going concern status. The telesurgery milestones, however, reinforce the investment narrative centered on regulatory progress and commercial expansion, particularly in Southeast Asia, which may support future U.S. and EU regulatory efforts. The stock’s sharp premarket rise reflects optimism about its telesurgery capabilities and market potential, despite lingering financial risks.